Plain English summary {#Sec1}
=====================

Long-acting reversible contraceptives such as intrauterine devices (IUDs) are among the most effective options for preventing pregnancy, and their popularity is increasing. However, whether changes in IUD use are associated with changes in rates of tubal sterilization, a largely irreversible and permanent contraceptive option, is unclear. In this study, we evaluated changes in rates of tubal sterilization, insertion of two different types of IUDs (copper or levonorgestrel \[LNG\] IUDs) and side effects associated with these devices over time. Data were obtained from an insurance claims database that included women aged 15 to 45 years who underwent insertion of copper or LNG IUD insertion or tubal sterilization between 1/1/2006 and 12/31/2011. Approximately 2 million women were included in the database each year. Between 2006 and 2011, copper IUD insertion rates increased from 0.18 to 0.25% and LNG IUD insertion rates increased from 0.63 to 1.15%, while sterilization claims decreased from 0.78 to 0.66%. Increases in IUD insertion were apparent in all age groups; decreases in tubal sterilization occurred in women aged 20 to 34 years. Results from our study suggest that increasing numbers of women are opting for copper and LNG IUDs over permanent sterilization.

Background {#Sec2}
==========

Intrauterine devices (IUDs) are the most common method of reversible contraception \[[@CR1], [@CR2]\], used by approximately 14.3% of reproductive-aged women worldwide \[[@CR3]\]. However, they are used only by 6.4% of American women using contraception \[[@CR4]\]. Two commonly used IUDs in the US include the copper T380A IUD (copper IUD) and the levonorgestrel 20-mcg-releasing intrauterine device (LNG IUD). Both IUDs have been shown to be cost effective, have few contraindications, and are well tolerated \[[@CR5]--[@CR9]\].

Although the use of both IUDs is low in the US compared with the rest of the world, data suggest that use has substantially increased in recent years \[[@CR10], [@CR11]\]. Factors that may affect IUD use, including changes in rates of tubal sterilization, complications, or side effects have not been investigated.

In this report, we compare the use and complications associated with the copper IUD, LNG IUD, and tubal sterilization using data obtained from the Optum™ Clinformatics™ Data Mart database.

Methods {#Sec3}
=======

The Optum™ Clinformatics™ Data Mart database is a large database of medical claims, pharmacy claims, lab results, and administrative data that contains information on patient characteristics, inpatient and outpatient encounters, and outpatient prescription drug coverage throughout the US. The database includes approximately 13 million unique individuals each year. Most individuals included in the database are commercially insured. The database is fully compliant with the Health Insurance Portability and Accountability Act.

This study evaluated claims from January 1, 2006, to December 31, 2011, among women aged 15--45 years as of the index date, defined as the insertion date of copper IUD (Healthcare Common Procedure Coding System \[HCPCS\] code J7300) or LNG IUD (HCPCS code J7302), or date of sterilization by tubal ligation/tubal occlusion, based on receipt of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 66.2 or 66.3 or Current Procedure Terminology codes 58600, 58605, 58611, 58615, 56870, or 56871.

Outcomes of interest included the rate of copper IUD insertion, LNG IUD insertion, and tubal sterilization by year (2006--2011) and by age group (ages 15--19, 20--24, 25--34, and 35--45), and changes in rate of potential complications and side effects over time. Complications and side effects were assessed based on receipt of ICD-9-CM codes for the following conditions: uterine perforation, pelvic inflammatory disease, post-insertion infection, dysmenorrhea, heavy menstrual bleeding (HMB), menorrhagia, anemia, ovarian cyst, pelvic pain, and amenorrhea.

All analyses were conducted using SAS®, version 9.3 (SAS Institute Inc., Cary, NC, USA). Chi square analyses were used to analyze categorical variables; analyses of variance were used to evaluate continuous variables. Findings with associated *P* values \<0.05 were considered statistically significant.

Results {#Sec4}
=======

The number of women included in the analysis each year ranged from 1,870,675 to 2,016,916. Rates of tubal sterilization decreased and rates of insertion of both copper and LNG IUDs increased between 2006 and 2011 (Table [1](#Tab1){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}). The percentage of women who underwent tubal ligation/tubal occlusion decreased from 0.78% (14,887/1,907,748) in 2006 to 0.66% (12,560/1,909,316) in 2011 (*P* \< 0.0001), while rates of copper IUD insertion increased from 0.18% (3,454/1,907,748) to 0.25% (4,682/1,909,316) (*P* \< 0.0001) and rates of LNG IUD insertion increased from 0.63% (12,028/1,907,748) to 1.15% (22,035/1,909,316) (*P* \< 0.0001) from 2006 to 2011, respectively.Table 1Rate of IUD insertion and tubal sterilization over timeCopper IUDLNG IUDTubal SterilizationYearTotal Nn (%)n (%)n (%)20061,907,7483454 (0.18)12,028 (0.63)14,887 (0.78) Age 15 to 19 y293,35452 (0.02)216 (0.07)38 (0.01) Age 20 to 24 y220,950330 (0.15)1257 (0.57)451 (0.20) Age 25 to 34 y566,1521735 (0.31)6230 (1.10)6642 (1.17) Age 35 to 45 y827,2921337 (0.16)4325 (0.52)7756 (0.94)20071,940,3013803 (0.20)16,789 (0.87)14,769 (0.76) Age 15 to 19 y299,59979 (0.03)416 (0.14)42 (0.01) Age 20 to 24 y224,324403 (0.18)1813 (0.81)444 (0.20) Age 25 to 34 y583,9551964 (0.34)8533 (1.46)6471 (1.11) Age 35 to 45 y832,4231357 (0.16)6027 (0.72)7812 (0.94)20082,001,7394474 (0.22)24,276 (1.21)14,667 (0.73) Age 15 to 19 y308,311102 (0.03)690 (0.22)21 (0.01) Age 20 to 24 y237,192455 (0.19)2845 (1.2)410 (0.17) Age 25 to 34 y615,5372368 (0.38)12,545 (2.04)6473 (1.05) Age 35 to 45 y840,6991549 (0.18)8196 (0.97)7763 (0.92)20092,016,9164868 (0.24)24,811 (1.23)14,881 (0.74) Age 15 to 19 y312,43193 (0.03)777 (0.25)37 (0.01) Age 20 to 24 y237,723460 (0.19)2920 (1.23)394 (0.17) Age 25 to 34 y625,3232578 (0.41)12,614 (2.02)6232 (1.00) Age 35 to 45 y841,4391737 (0.21)8500 (1.01)8218 (0.98)20101,870,6755246 (0.28)20,639 (1.10)13,313 (0.71) Age 15 to 19 y289,736142 (0.05)677 (0.23)37 (0.010 Age 20 to 24 y222,812551 (0.25)2101 (0.94)243 (0.11) Age 25 to 34 y574,7022782 (0.48)10,316 (1.8)5485 (0.95) Age 35 to 45 y783,4251771 (0.23)7545 (0.96)7548 (0.96)20111,909,3164682 (0.25)22,035 (1.15)12,560 (0.66) Age 15 to 19 y295,377116 (0.04)762 (0.26)24 (0.01) Age 20 to 24 y265,891601 (0.23)2648 (1.00)280 (0.11) Age 25 to 34 y575,7292451 (0.43)10,694 (1.86)5102 (0.89) Age 35 to 45 y772,3191514 (0.20)7931 (1.03)7154 (0.93)*P* Value for Trend Over Time in the Overall Population\<0.0001\<0.0001\<0.0001 Fig. 1Rate of claims related to copper IUD insertion, LNG IUD insertion, and tubal sterilization by year of insertion/sterilization

Increases in IUD insertion and decreases in tubal sterilization rates were apparent in most age groups (Table [1](#Tab1){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}). The greatest decreases in rates of sterilization occurred in women ages 25--34. Although insertion of either IUD in adolescents ages 15--19 was rare, the copper IUD insertion rate doubled and the LNG IUD insertion rate more than tripled in this age group between 2006 and 2011.Fig. 2Rate of claims related to copper IUD insertion, LNG IUD insertion, and tubal sterilization by year of insertion or sterilization in women aged 15 to 19 years (**a**), 20 to 24 years (**b**), 25 to 34 years (**c**), and 35 to 45 years (**d**)

Rates of complications or side effects were low and are shown in Table [2](#Tab2){ref-type="table"}. The most common side effects and complications were amenorrhea (7.36--11.59%), HMB (4.85--15.69%), and pelvic pain (11.12--14.27%). Significant increases over time were observed in rates of perforation of the uterine wall in all groups, HMB and menorrhagia with LNG IUD and tubal sterilization, dysmenorrhea and anemia with sterilization, and ovarian cysts with LNG IUD. A significant decrease in pelvic inflammatory disease was observed over time among women who underwent sterilization.Table 2Complications and side effects associated with IUD insertion and tubal sterilization over timeCopper IUDLNG IUDTubal SterilizationComplications/Side Effectn (%)n (%)n (%)Amenorrhea (ICD-9 626.0) Total (2006--2011)2385 (8.99)^ab^9077 (7.53)^ac^7050 (11.67)^bc^ 2006308 (8.92)941 (7.82)1638 (11.00) 2007381 (10.02)1278 (7.61)1614 (10.93) 2008412 (9.21)1873 (7.72)1700 (11.59) 2009448 (9.20)1845 (7.44)1658 (11.14) 2010452 (8.62)1518 (7.36)1429 (10.73) 2011384 (8.20)1622 (7.36)1371 (10.92)*P* Value0.07750.41910.2768Anemia (ICD-9 280.xx) Total (2006--2011)595 (2.24)^b^2832 (2.35)^c^2003 (3.32)^bc^ 200667 (1.94)279 (2.32)435 (2.92) 200778 (2.05)386 (2.30)433 (2.93) 2008106 (2.37)538 (2.22)492 (3.35) 2009119 (2.44)600 (2.42)513 (3.45) 2010135 (2.57)512 (2.48)481 (3.61) 201190 (1.92)517 (2.35)469 (3.73)*P* Value0.14960.52430.0001Dysmenorrhea (ICD-9 625.3) Total (2006--2011)733 (2.76)^ab^3909 (3.24)^ac^2491 (4.12)^bc^ 200690 (2.61)378 (3.14)587 (3.94) 200785 (2.50)566 (3.37)591 (4.00) 2008132 (2.95)723 (2.98)598 (4.08) 2009139 (2.86)807 (3.25)647 (4.35) 2010137 (2.61)692 (3.35)649 (4.87) 2011140 (2.99)743 (3.37)606 (4.82)*P* Value0.63880.1234\<0.0001Heavy Menstrual Bleeding (ICD-9 626.2) Total (2006--2011)1370 (5.16)^ab^10 204 (8.46)^ac^7328 (12.13)^bc^ 2006204 (5.91)1048 (8.71)1687 (11.33) 2007198 (5.21)1406 (8.37)1750 (11.85) 2008224 (5.01)1846 (7.60)1922 (13.10) 2009256 (5.26)1992 (8.03)2045 (13.74) 2010261 (4.98)1881 (9.11)2006 (15.07) 2011227 (4.85)2031 (9.22)1971 (15.69)*P* Value0.3527\<0.0001\<0.0001Infection (ICD-9 998.5x) Total (2006--2011)15 (0.06)88 (0.07)^c^18 (0.03)^c^ 20064 (0.12)12 (0.10)2 (0.01) 20071(0.03)14 (0.08)2 (0.01) 20086 (0.13)15 (0.06)7 (0.05) 20092 (0.04)25 (0.10)4 (0.03) 20100 (0.00)14 (0.07)4 (0.03) 20112 (0.04)8 (0.04)5 (0.04)*P* Value0.05430.12550.4301Menorrhagia (ICD-9 627.0) Total (2006--2011)53 (0.20)^ab^528 (0.44)^ac^410 (0.68)^bc^ 200612 (0.35)48 (0.40)88 (0.59) 20076 (0.16)58 (0.35)94 (0.64) 200811 (0.25)84 (0.35)92 (0.63) 200912 (0.25)89 (0.36)119 (0.80) 20108 (0.15)121 (0.59)121 (0.91) 20114 (0.09)128 (0.58)126 (1.00)*P* Value0.1181\<0.0001\<0.0001Ovarian Cyst (ICD-9 620.2) Total (2006--2011)1157 (4.36)^ab^6340 (5.26)^ac^4324 (7.16)^bc^ 2006140 (4.05)539 (4.48)1045 (7.02) 2007155 (4.08)786 (4.68)990 (6.70) 2008211 (4.72)1268 (5.22)1076 (7.34) 2009209 (4.29)1400 (5.64)1039 (6.98) 2010223 (4.25)1142 (5.53)1003 (7.53) 2011219 (4.68)1205 (5.47)910 (7.25)*P* Value0.5197\<0.00010.0975Pelvic Inflammatory Disease (ICD-9 614.xx--616.xx) Total (2006--2011)5053 (19.05)^ab^19 063 (15.81)^ac^11 162 (18.48)^bc^ 200613 (0.38)40 (0.33)64 (0.43) 200712 (0.32)53 (0.32)66 (0.45) 200823 (0.51)74 (0.30)69 (0.47) 200915 (0.31)60 (0.24)54 (0.37) 201012 (0.23)49 (0.24)41 (0.31) 201118 (0.38)58 (0.26)25 (0.20)*P* Value0.2820.37270.02Pelvic Pain (ICD-9 625.9, 789.00) Total (2006--2011)3222 (12.15)^ab^13 891 (11.52)^ac^8323 (13.78)^bc^ 2006384 (11.12)1395 (11.60)1987 (13.35) 2007466 (12.25)1915 (11.41)1997 (13.52) 2008519 (11.60)2729 (11.24)1976 (13.47) 2009627 (12.88)2897 (11.68)2117 (14.23) 2010661 (12.60)2419 (11.72)1881 (14.13) 2011565 (12.07)2536 (11.51)1792 (14.27)*P* Value0.14490.6170.0593Perforation of Uterine Wall (ICD-9 621.8, 665.3) Total (2006--2011)412 (1.55)^ab^1558 (1.29)^ac^387 (0.64)^bc^ 200640 (1.16)142 (1.18)57 (0.38) 200751 (1.34)176 (1.05)76 (0.51) 200848 (1.07)301 (1.24)91 (0.62) 200988 (1.81)319 (1.29)119 (0.80) 201098 (1.87)307 (1.49)103 (0.77) 201187 (1.86)313 (1.42)109 (0.87)*P* Value0.00140.0023\<0.0001^abc^Chi square pairwise comparisons between groups with the same superscript, *P* \< 0.05. The pairwise comparisons were done for the total for each complication/side effect across years 2006--2011 and not for the individual years

Discussion {#Sec5}
==========

Results indicate that tubal sterilization rates decreased and IUD insertion rates increased between 2006 and 2011. These findings were noted across all age groups, with the exception of sterilization in women ages 35--45, the rates of which were constant. By 2008, insertion rates of LNG IUD exceeded rates of sterilization in every age group, including women ages 35--45. Importantly, substantial increases in insertion rates for both the copper and LNG IUDs were seen in younger women, including adolescents.

Results suggesting an increase in IUD use are consistent with data from the National Survey of Family Growth, which showed that from 2002 to 2013, the prevalence of IUD use increased from 2.0 to 10.3% among female contraceptive users aged 15--44 years \[[@CR12]\]. The prevalence of female sterilization in the same population decreased from 27.0 to 25.1% over the same time period. In a separate analysis of sexually active women aged 15--24 years, IUD use increased from 0.2 to 2.5% in teens ages 15--19 and from 2.0 to 5.4% in women aged 20--24 years, although the increase was primarily observed in parous women \[[@CR11]\]. Another retrospective cohort study found that IUD insertion rates increased nearly 7-fold between 2002 and 2009 \[[@CR6]\].

Importantly, women experienced few complications with either IUD. Differences in complication rates between IUDs were of minimal clinical significance. The most frequent complications in both IUD groups were menstrual disorders and pelvic pain; however, patients who underwent tubal sterilization reported these adverse effects more frequently than IUD users. The most serious complications associated with IUD use, such as uterine perforation and pelvic inflammatory disease, were reported in fewer than 2% of women.

Limitations of the study included its observational, retrospective nature, lack of representation of women without health insurance, and nature of claims databases. Despite these limitations, our findings confirm recent data suggesting a shift toward long-acting reversible contraceptive methods and away from permanent methods. Copper IUD and LNG IUD insertion and tubal sterilization were associated with a low rate of complications.

Conclusions {#Sec6}
===========

Our analysis of a retrospective claims database supported an increase in women selecting reversible methods of long-term contraception over permanent tubal sterilization, as shown by an increase in copper IUD and LNG IUD insertion rates and decreased sterilization rates between 2006 and 2011. Younger women showed substantial increases in IUD insertion rates. Among all women, rates of complications or side effects were low.

HCPCS

:   Healthcare Common Procedure Coding System

HMB

:   Heavy menstrual bleeding

ICD-9-CM

:   International Classification of Diseases, Ninth Revision, Clinical Modification

IUD

:   Intrauterine device

LNG

:   Levonorgestrel
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